Benzinga

A veteran trader has publicly predicted that Bitcoin could climb as high as $600,000 in a best-case scenario. The forecast, circulated via financial news outlet Benzinga, is drawing attention from crypto investors weighing bullish outlooks against the asset's well-known volatility. No timeline or detailed reasoning for the price target was included in the initial report.

Kodiak Sciences announced that its experimental eye drug performs on par with Regeneron's established treatment, according to a Benzinga report. The claim, if supported by trial data, would position the biotech as a credible challenger in the competitive market for retinal disease therapies, where Regeneron's medicine has long been a dominant option.

AMC Entertainment shares are drawing attention as investors ask what is driving the movie theater chain's stock movement on Monday. Benzinga highlights the question, reflecting renewed interest in the company among retail traders who have long tracked its volatile price swings. No specific cause for Monday's move has been confirmed.

Financial advisor Ric Edelman has reiterated his prediction that Bitcoin will reach $500,000 by 2030, dismissing short-term price fluctuations as unimportant. The comment, reported by Benzinga, restates a forecast he has made before, and suggests investors should focus on the long-term trajectory rather than day-to-day market swings. The bold target is drawing attention in crypto circles as Bitcoin remains a divisive asset among financial professionals.